Top Page
Aurora Labs
(Sydney:A3D)
Aurora Labs (A3D) vs. iShares MSCI Australia ETF (EWA)
Aurora Labs Business Overview & Revenue Model
Aurora Labs Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 708.31K | 743.83K | 174.30K | 134.56K | 32.20K | 171.62K |
| Gross Profit | -1.37M | 326.65K | 57.13K | 58.81K | 13.89K | -145.00K |
| EBITDA | -4.77M | -4.54M | -3.23M | -3.37M | -3.70M | -4.81M |
| Net Income | -4.05M | -3.75M | -2.81M | -2.96M | -3.15M | -4.42M |
Balance Sheet | ||||||
| Total Assets | 5.77M | 2.91M | 3.08M | 2.18M | 3.35M | 2.91M |
| Cash, Cash Equivalents and Short-Term Investments | 3.65M | 1.16M | 1.65M | 986.80K | 1.95M | 1.37M |
| Total Debt | 232.00K | 956.01K | 842.94K | 65.39K | 160.53K | 252.00K |
| Total Liabilities | 1.40M | 1.84M | 1.30M | 719.35K | 716.58K | 711.20K |
| Stockholders Equity | 4.37M | 1.07M | 1.78M | 1.46M | 2.63M | 2.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.21M | -2.80M | -2.41M | -2.60M | -2.68M | -1.68M |
| Operating Cash Flow | -3.22M | -2.62M | -2.40M | -2.57M | -2.63M | -1.68M |
| Investing Cash Flow | -988.63K | -180.58K | -7.69K | -23.07K | -48.42K | 6.86K |
| Financing Cash Flow | 5.68M | 2.31M | 3.07M | 1.63M | 3.25M | 1.72M |
Aurora Labs Technical Analysis
Aurora Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
61 Neutral | AU$58.17M | 7.32 | 17.89% | 0.49% | -8.28% | 89.71% | |
57 Neutral | AU$14.17M | 3.85 | 13.83% | ― | -6.52% | -20.79% | |
55 Neutral | AU$266.72M | -3.91 | -39.81% | ― | 722.02% | -0.77% | |
50 Neutral | AU$29.32M | -2.24 | -148.94% | ― | 327.10% | 1.01% | |
50 Neutral | AU$17.44M | 7.14 | 4.57% | 4.32% | -15.54% | -26.61% | |
41 Neutral | AU$102.22M | -4.86 | -35.18% | ― | 0.88% | 4.88% |
Aurora Labs Corporate Events
Aurora Labs Limited has reported a change in director David Trimboli’s interests, detailing additional ordinary shares acquired through his investment vehicle, Seefeld Investments Pty Ltd. Following an on-market trade on 16 March 2026, Seefeld’s holding increased to 6,757,841 fully paid ordinary shares, while Trimboli’s direct holding remained at 515,160 shares.
The transaction, valued at $24,681.38 for 474,642 newly acquired ordinary shares, leaves Trimboli’s suite of options unchanged, including listed and unlisted options with various strike prices and expiries. The company confirmed that the trades did not occur during a closed period, indicating routine portfolio adjustment and adherence to ASX disclosure and governance requirements.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has notified the ASX of a proposed issue of up to 28 million unlisted options as part of a placement or similar capital-raising mechanism. The options, which form a new class of unlisted securities, are scheduled for issue on 9 April 2026 and underscore the company’s ongoing use of equity-linked instruments to fund operations and support its strategic objectives.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has called a general meeting of shareholders for 9 April 2026 in Perth, where resolutions will be decided by poll based on both proxy votes and those of shareholders attending in person. The company is shifting to primarily digital distribution of meeting materials, encouraging shareholders to access the notice of meeting online, lodge directed proxy votes ahead of the deadline, and submit questions in advance, underscoring a continued move toward more efficient, technology-driven investor communications.
Shareholders who have elected to receive electronic communications will be emailed a link to the meeting documentation and are advised to seek professional guidance if uncertain about how to vote on the resolutions. The board-approved announcement also notes that any changes to meeting arrangements will be communicated via the ASX platform and the company’s website, highlighting an emphasis on transparency and timely market disclosure around governance processes.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has called a general meeting of shareholders to be held in Perth on 9 April 2026, with proxy votes due by 7 April 2026, to consider key governance and remuneration matters. The main item on the agenda is shareholder approval for the proposed issue of up to 2,500,000 options to director Andrew Bottrell or his nominees, a move that could affect the company’s capital structure and aligns executive incentives more closely with shareholder interests.
The company has set the share register record date for voting eligibility at 7 April 2026 and confirmed that all resolutions will be decided by poll, reinforcing a more granular and transparent voting process. Voting exclusions will apply to Bottrell and related parties to manage conflicts of interest, underscoring a focus on compliance with ASX listing rules and Australian corporations law, and signalling attention to governance standards for existing and prospective investors.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Ltd has appointed Andrew Bottrell as a director effective 4 March 2026, according to an initial director’s interest notice lodged with the ASX. The filing shows that Bottrell holds no relevant interests in Aurora Labs securities, either directly, indirectly, or through related contracts at the time of his appointment.
The appointment, coupled with the absence of any shareholding or contractual interest, indicates that Bottrell joins the board without an existing equity stake in the company. This clean-interest position may be relevant for investors monitoring governance changes and potential future alignment of director incentives with shareholder interests.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has strengthened its board with the appointment of retired Major General Andrew Bottrell as a non-executive director, effective 5 March 2026, adding nearly four decades of senior defence and national security experience. Bottrell brings extensive operational, procurement and whole-of-government expertise, including leadership of key Australian Defence Force acquisition programs and national security operations.
In his new role, Bottrell will provide strategic oversight across defence engagement, capability development, government liaison and international partner alignment to support Aurora Labs’ expansion in sovereign and allied defence markets. His appointment, which includes options and partial equity-based director fees subject to shareholder approval, is positioned to reinforce the company’s governance, defence networks and growth trajectory, particularly in collaboration with major defence partners.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has issued 259,924 fully paid ordinary shares as a result of the conversion of an equivalent number of share rights granted under its Employee Incentive Scheme. The move modestly increases the company’s share capital while reinforcing its strategy of using equity incentives to attract and retain staff without undertaking a separate public disclosure process.
The company confirmed that these securities were issued without a prospectus in reliance on provisions of the Corporations Act and that it remains compliant with its financial reporting and continuous disclosure obligations. Aurora Labs also stated there is no excluded information that would be required to be disclosed, aiming to reassure investors that the issuance does not conceal any undisclosed material developments.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has disclosed a change in director David Trimboli’s interests, following the issue and subsequent conversion of 259,924 share rights into ordinary shares. The transaction, valued at $11,956.52, increased Trimboli’s direct holding to 515,160 fully paid ordinary shares, while his indirect holdings through Seefeld Investments and associated options remain unchanged.
The share rights were issued in lieu of cash directors’ fees for the period from mid-November to the end of December, indicating the company’s use of equity-based remuneration to conserve cash and align director incentives with shareholder interests. The notice confirms that the changes did not occur during a closed period and therefore did not require special trading clearance under ASX rules.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has applied for quotation on the ASX of 259,924 new ordinary fully paid shares, to be issued on March 3, 2026, under its existing ticker A3D. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly increasing the company’s quoted share capital and potentially broadening its tradable float for investors.
The move reflects routine capital management activity as Aurora Labs updates the market on changes to its listed equity base, in line with ASX disclosure requirements. While the issuance is relatively small in scale, it incrementally adjusts the company’s capital structure and may have minor implications for liquidity and shareholder dilution depending on overall market conditions.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has notified the market of the issue of 259,924 unquoted share rights under an employee incentive scheme, with an issue date of 27 February 2026. These securities are not intended to be quoted on the ASX, indicating the company is using equity-based remuneration to incentivise or retain staff without immediately affecting the volume of tradable shares on the market.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited reported revenue of $201,219 for the six months to 31 December 2025, down 15% from the prior corresponding period, highlighting ongoing commercial challenges in growing its top line. The company’s net tangible assets per ordinary share stood at 0.8 cents at period end, underscoring a relatively thin asset base for shareholders and reflecting its early-stage profile.
The half-year loss after tax widened 12% to $2.89 million compared with the previous year as expenses continued to outpace revenue, and no dividends were declared or reinvestment plans offered, reinforcing a focus on conserving cash and reinvestment over shareholder payouts. The interim financial report has been audit reviewed without dispute or qualification, providing investors with assurance on the reliability of the disclosed figures despite the ongoing losses.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has disclosed a change in director David Trimboli’s interests in the company’s securities, following an on‑market purchase of 255,236 ordinary shares over 5–6 February 2026. The transaction, valued at $13,772.27, adds to Trimboli’s existing direct and indirect holdings, including a substantial package of options exercisable at various strike prices and expiries.
The new shares are held directly by Trimboli, while his pre‑existing share and option interests remain held through Seefeld Investments Pty Ltd as well as in his own name. The disclosure, lodged under ASX listing rules, signals continued insider support for Aurora Labs’ equity and provides investors with updated transparency on a key director’s ownership position.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs reported progress in the December 2025 quarter as it accelerates the commercialisation of its metal additive manufacturing technology and broadens its market exposure beyond development into early-stage deployment. The company formally entered the defence propulsion market through a joint testing and commercialisation agreement with Sovereign Propulsion Systems, securing a maiden $250,000 order for 20 AU4 micro gas turbine propulsion systems that will be tested in bench and flight operations and position Aurora as a recognised supplier to defence. It also deepened its strategic presence in defence and aerospace by signing MOUs with European missile group MBDA and Australian precision armaments manufacturer Ares Armaments, while upgrading its Canning Vale facility with new CNC machinery, expanding industrial 3D-printing revenues including a defence metal-printing order, advancing AS9100D certification, and completing a $5.5 million capital raising and board restructure to underpin near-term growth.
The most recent analyst rating on (AU:A3D) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has disclosed a change in director Rebekah Letheby’s interests, with her indirect holdings managed through a jointly held account. Letheby exercised 180,302 options at $0.045 each, converting them into fully paid ordinary shares for a cash consideration of $8,113.59, increasing her total direct shareholding to 540,907 ordinary shares while maintaining 3,000,000 unlisted options exercisable at $0.14 and an unchanged indirect holding of 400,000 shares. The transaction, which did not occur during a closed trading period, marginally boosts director equity alignment with shareholders, signalling confidence in the company’s prospects without altering existing option-based incentive structures.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has disclosed a change in the interests of director David Trimboli, who holds his stake indirectly through Seefeld Investments Pty Ltd. Trimboli exercised 1,916,666 options at $0.045 each, paying a total of $86,249.97, which converted into an equivalent number of fully paid ordinary shares and increased his holding to 6,283,199 shares, while the corresponding options lapsed. The transaction, which did not occur during a closed trading period, signals continued insider commitment to the company’s equity and modestly reshapes the director’s exposure from options to ordinary shares, potentially aligning his interests more closely with those of other shareholders.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has announced the cessation of 37,776,525 options (ASX code A3DAI), which expired unexercised on 22 December 2025. The expiry of this large tranche of options reduces the company’s potential future share dilution, effectively tightening its capital structure and potentially altering the balance of incentives for existing shareholders and option holders as the company progresses with its strategic plans.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs has issued 14,681,487 fully paid ordinary shares following the conversion of an equivalent number of options exercisable at $0.045 and expiring on 22 December 2025, expanding its share capital without undertaking a formal disclosure offering. The company confirmed it has complied with its financial reporting and continuous disclosure obligations under the Corporations Act and stated there is no excluded information, signalling regulatory compliance and transparency as it adjusts its capital structure, a move of interest to existing shareholders and potential investors monitoring dilution and funding pathways.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.
Aurora Labs Limited has applied to list 14,681,487 new fully paid ordinary shares on the Australian Securities Exchange, with the securities to be quoted under the ticker A3D from 23 December 2025. The issuance, arising from the exercise or conversion of existing options or other convertible securities, will expand the company’s quoted share base and may influence its capital structure, liquidity, and market valuation as the additional stock comes onto the market.
The most recent analyst rating on (AU:A3D) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Aurora Labs stock, see the AU:A3D Stock Forecast page.